Renaissance Capital logo

LianBio Priced, Nasdaq: LIAN

Developing in-licensed therapies for a variety of indications in China.

Industry: Health Care

Latest Trade: $0.29 -0.03 (-9.1%)

First Day Return: -14.4%

Return from IPO: -98.0%

Industry: Health Care

We are a global, science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. We have purposefully designed our organization to successfully execute on our vision by identifying, sourcing, developing and commercializing product candidates and partnering with highly innovative biopharmaceutical companies around the world. We are establishing an international infrastructure to position ourselves as a partner of choice with a platform to provide access to our target markets. Our model leverages a number of key elements, including transformative in-licensing, development and commercialization approaches that we believe will enable us to deliver innovative therapeutic solutions to patients in Greater China, including Mainland China, Hong Kong, Taiwan and Macau, and other Asian markets. Our deep relationships with our founder, Perceptive Advisors (“Perceptive”), as well as our broader investor base, position us to access and capture attractive business development opportunities. We have also entered into high-value strategic collaborations with Pfizer Inc. (“Pfizer”), which offers optionality to leverage its broad reach and commercial infrastructure in Greater China, and BridgeBio Pharma LLC (“BridgeBio”), which provides preferential access to an innovative pipeline of more than 20 product candidates in development.
more less
IPO Data
IPO File Date 10/01/2021
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 20.3
Deal Size ($mm) $325
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/31/2021
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 20.3
Deal Size ($mm) $325
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Goldman Sachs
Jefferies
more
Company Data
Headquarters Shanghai, China
Founded 2019
Employees at IPO 87
Website www.lianbio.com

LianBio (LIAN) Performance